JP2010042007A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010042007A5 JP2010042007A5 JP2009211970A JP2009211970A JP2010042007A5 JP 2010042007 A5 JP2010042007 A5 JP 2010042007A5 JP 2009211970 A JP2009211970 A JP 2009211970A JP 2009211970 A JP2009211970 A JP 2009211970A JP 2010042007 A5 JP2010042007 A5 JP 2010042007A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- kda
- activated
- lymphocytes
- measured
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19741929 | 1997-09-23 | ||
| DE19821060A DE19821060A1 (de) | 1997-09-23 | 1998-05-11 | Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung |
| DE19821060.4 | 1998-05-11 | ||
| DE19741929.1 | 1998-05-11 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000512857A Division JP4463418B2 (ja) | 1997-09-23 | 1998-09-23 | Ｔ細胞共同刺激性ポリペプチド、モノクローナル抗体、ならびにその製法および使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010042007A JP2010042007A (ja) | 2010-02-25 |
| JP2010042007A5 true JP2010042007A5 (https=) | 2010-12-09 |
| JP5021008B2 JP5021008B2 (ja) | 2012-09-05 |
Family
ID=7843330
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009211970A Expired - Fee Related JP5021008B2 (ja) | 1997-09-23 | 2009-09-14 | Ｔ細胞共同刺激性ポリペプチド、モノクローナル抗体、ならびにその製法および使用 |
Country Status (3)
| Country | Link |
|---|---|
| US (6) | US7132099B2 (https=) |
| JP (1) | JP5021008B2 (https=) |
| DE (1) | DE19821060A1 (https=) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7112655B1 (en) | 1997-02-27 | 2006-09-26 | Japan Tobacco, Inc. | JTT-1 protein and methods of inhibiting lymphocyte activation |
| JP3521382B2 (ja) | 1997-02-27 | 2004-04-19 | 日本たばこ産業株式会社 | 細胞間接着及びシグナル伝達を媒介する細胞表面分子 |
| US7259247B1 (en) * | 1997-09-23 | 2007-08-21 | Bundersrespublik Deutschaland Letztvertreten Durch Den Direktor Des Robert-Koch-Institutes | Anti-human T-cell costimulating polypeptide monoclonal antibodies |
| DE19821060A1 (de) * | 1997-09-23 | 1999-04-15 | Bundesrepublik Deutschland Let | Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung |
| WO2000019988A1 (en) * | 1998-10-07 | 2000-04-13 | Millennium Pharmaceuticals, Inc. | NOVEL Th2-SPECIFIC MOLECULES AND USES THEREOF |
| US7435796B1 (en) | 1999-02-03 | 2008-10-14 | Amgen Inc. | Antibodies which bind B7RP1 |
| DK1149114T3 (da) * | 1999-02-03 | 2014-06-23 | Amgen Inc | Polypeptider, der er involveret ved et immunrespons |
| US7708993B2 (en) * | 1999-02-03 | 2010-05-04 | Amgen Inc. | Polypeptides involved in immune response |
| US8624010B1 (en) | 1999-02-03 | 2014-01-07 | Steven K. Yoshinaga | Nucleic acids encoding B7RP1 |
| DE19936035C2 (de) * | 1999-07-30 | 2002-11-21 | Univ Leipzig | Lymphozytenproliferationstestkit |
| JP4210454B2 (ja) | 2001-03-27 | 2009-01-21 | 日本たばこ産業株式会社 | 炎症性腸疾患治療剤 |
| JP3871503B2 (ja) | 1999-08-30 | 2007-01-24 | 日本たばこ産業株式会社 | 免疫性疾患治療剤 |
| JP3597140B2 (ja) | 2000-05-18 | 2004-12-02 | 日本たばこ産業株式会社 | 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途 |
| CN101498731A (zh) * | 2000-05-18 | 2009-08-05 | 日本烟草产业株式会社 | 抗协同刺激信号转导分子ailim的人单克隆抗体及其药物用途 |
| JP4212278B2 (ja) | 2001-03-01 | 2009-01-21 | 日本たばこ産業株式会社 | 移植片拒絶反応抑制剤 |
| WO2005068662A1 (en) * | 2003-12-30 | 2005-07-28 | Sigma-Aldrich Co. | Rapid preparation of nucleic acids by enzymatic digestion |
| AU2005235718B2 (en) | 2004-04-23 | 2011-09-22 | Bundesrepublik Deutschland Letztvertreten Durch Das Robert-Koch-Institut Vertreten Durch Seinen Prasidenten | Method for the treatment of T cell mediated conditions by depletion of icos-positive cells in vivo |
| EP3375791A1 (en) | 2009-09-30 | 2018-09-19 | Memorial Sloan Kettering Cancer Center | Combination immunotherapy for the treatment of cancer |
| ES2724451T3 (es) | 2010-02-04 | 2019-09-11 | Univ Pennsylvania | ICOS regula fundamentalmente la expansión y la función de linfocitos Th17 humanos inflamatorios |
| ES2635335T3 (es) | 2010-09-20 | 2017-10-03 | Biontech Cell & Gene Therapies Gmbh | Receptores de células T específicos de antígeno y epítopos de células T |
| ES2612914T3 (es) * | 2011-03-31 | 2017-05-19 | Inserm - Institut National De La Santé Et De La Recherche Médicale | Anticuerpos dirigidos contra Icos y usos de los mismos |
| CN104968364A (zh) | 2012-12-03 | 2015-10-07 | 百时美施贵宝公司 | 强化免疫调变性Fc融合蛋白的抗癌活性 |
| US9458246B2 (en) | 2013-03-13 | 2016-10-04 | Amgen Inc. | Proteins specific for BAFF and B7RP1 |
| PH12022550138A1 (en) | 2013-03-13 | 2023-03-06 | Amgen Inc | Proteins specific for baff and b7rp1 and uses thereof |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| MA41414A (fr) * | 2015-01-28 | 2017-12-05 | Centre Nat Rech Scient | Protéines de liaison agonistes d' icos |
| TWI719970B (zh) | 2015-03-23 | 2021-03-01 | 美商永斯醫療股份有限公司 | 針對ｉｃｏｓ之抗體 |
| EP3365372A1 (en) | 2015-10-22 | 2018-08-29 | Jounce Therapeutics, Inc. | Gene signatures for determining icos expression |
| KR102379464B1 (ko) | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| WO2018029474A2 (en) | 2016-08-09 | 2018-02-15 | Kymab Limited | Anti-icos antibodies |
| KR20260030924A (ko) | 2016-08-09 | 2026-03-06 | 키맵 리미티드 | 항-icos 항체 |
| EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| TWI788340B (zh) | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | 抗icos促效劑抗體及其用途 |
| GB201709808D0 (en) | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
| EP3728314A1 (en) | 2017-12-19 | 2020-10-28 | Kymab Limited | Bispecific antibody for icos and pd-l1 |
| GB201721338D0 (en) | 2017-12-19 | 2018-01-31 | Kymab Ltd | Anti-icos Antibodies |
| PE20210665A1 (es) | 2018-03-23 | 2021-03-31 | Bristol Myers Squibb Co | Anticuerpos contra mica y/o micb y sus usos |
| EP3977132A1 (en) | 2019-05-30 | 2022-04-06 | Bristol-Myers Squibb Company | Cell localization signature and combination therapy |
| JP2022534967A (ja) | 2019-05-30 | 2022-08-04 | ブリストル－マイヤーズ スクイブ カンパニー | 多腫瘍遺伝子シグネチャーおよびその使用 |
| KR20220016155A (ko) | 2019-05-30 | 2022-02-08 | 브리스톨-마이어스 스큅 컴퍼니 | 면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법 |
| LT4051708T (lt) | 2019-10-28 | 2025-04-10 | Medimmune Limited | Užkrūčio liaukos stromos limfopoetiną (tslp) surišančių antikūnų sausų miltelių pavidalo vaisto formos ir jų panaudojimo būdai |
| GB202007099D0 (en) | 2020-05-14 | 2020-07-01 | Kymab Ltd | Tumour biomarkers for immunotherapy |
| AU2021334361A1 (en) | 2020-08-31 | 2023-05-11 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
| WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
| JP2024501029A (ja) | 2020-12-28 | 2024-01-10 | ブリストル－マイヤーズ スクイブ カンパニー | Ｐｄ１／ｐｄ－ｌ１抗体の皮下投与 |
| SMT202500208T1 (it) | 2020-12-28 | 2025-07-22 | Bristol Myers Squibb Co | Composizioni anticorpali e metodi per il loro uso |
| JP2024514530A (ja) | 2021-04-02 | 2024-04-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 切断型ｃｄｃｐ１に対する抗体およびその使用 |
| US20220396623A1 (en) | 2021-05-18 | 2022-12-15 | Kymab Limited | Uses of anti-icos antibodies |
| GB202107994D0 (en) | 2021-06-04 | 2021-07-21 | Kymab Ltd | Treatment of cancer |
| EP4493575A1 (en) | 2022-03-18 | 2025-01-22 | Bristol-Myers Squibb Company | Methods of isolating polypeptides |
| US20250340641A1 (en) | 2022-05-18 | 2025-11-06 | Kymab Limited | Uses of anti-icos antibodies |
| EP4531916A1 (en) | 2022-06-02 | 2025-04-09 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
| WO2024054992A1 (en) | 2022-09-09 | 2024-03-14 | Bristol-Myers Squibb Company | Methods of separating chelator |
| WO2024196952A1 (en) | 2023-03-20 | 2024-09-26 | Bristol-Myers Squibb Company | Tumor subtype assessment for cancer therapy |
| CN121712571A (zh) | 2023-08-15 | 2026-03-20 | 百时美施贵宝公司 | 陶瓷羟基磷灰石色谱流通法 |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8801537D0 (sv) | 1988-04-26 | 1988-04-26 | Ellco Food Ab | Cellodlingsmedium samt forfarande for dess framstellning |
| KR900702370A (ko) | 1988-10-06 | 1990-12-06 | 제임스 디. 그랜트 | 가용성 t세포 표면분자를 사용하는 치료 및 진단방법 |
| JP3521382B2 (ja) | 1997-02-27 | 2004-04-19 | 日本たばこ産業株式会社 | 細胞間接着及びシグナル伝達を媒介する細胞表面分子 |
| US7112655B1 (en) | 1997-02-27 | 2006-09-26 | Japan Tobacco, Inc. | JTT-1 protein and methods of inhibiting lymphocyte activation |
| DE19821060A1 (de) * | 1997-09-23 | 1999-04-15 | Bundesrepublik Deutschland Let | Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung |
| US7259247B1 (en) | 1997-09-23 | 2007-08-21 | Bundersrespublik Deutschaland Letztvertreten Durch Den Direktor Des Robert-Koch-Institutes | Anti-human T-cell costimulating polypeptide monoclonal antibodies |
| WO2000019988A1 (en) * | 1998-10-07 | 2000-04-13 | Millennium Pharmaceuticals, Inc. | NOVEL Th2-SPECIFIC MOLECULES AND USES THEREOF |
| DK1149114T3 (da) * | 1999-02-03 | 2014-06-23 | Amgen Inc | Polypeptider, der er involveret ved et immunrespons |
| JP4210454B2 (ja) * | 2001-03-27 | 2009-01-21 | 日本たばこ産業株式会社 | 炎症性腸疾患治療剤 |
| JP3597140B2 (ja) * | 2000-05-18 | 2004-12-02 | 日本たばこ産業株式会社 | 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途 |
| JP4212278B2 (ja) * | 2001-03-01 | 2009-01-21 | 日本たばこ産業株式会社 | 移植片拒絶反応抑制剤 |
-
1998
- 1998-05-11 DE DE19821060A patent/DE19821060A1/de not_active Withdrawn
-
2001
- 2001-04-02 US US09/823,307 patent/US7132099B2/en not_active Expired - Lifetime
- 2001-10-04 US US09/972,524 patent/US7125551B2/en not_active Expired - Lifetime
-
2003
- 2003-08-22 US US10/647,072 patent/US7306800B2/en not_active Expired - Fee Related
-
2007
- 2007-10-23 US US11/977,342 patent/US20090074784A1/en not_active Abandoned
- 2007-10-23 US US11/977,334 patent/US7722872B2/en not_active Expired - Fee Related
-
2009
- 2009-09-14 JP JP2009211970A patent/JP5021008B2/ja not_active Expired - Fee Related
-
2010
- 2010-03-26 US US12/732,360 patent/US20120045447A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010042007A5 (https=) | ||
| JP2001517425A5 (https=) | ||
| JP7270001B2 (ja) | Ｍｈｃクラスｉｉ拘束性ｍａｇｅ－ａ３を認識するｔ細胞受容体 | |
| Auerbach et al. | Identification of the platelet-derived chemokine CXCL4/PF-4 as a broad-spectrum HIV-1 inhibitor | |
| Song et al. | Understanding kidney injury molecule 1: a novel immune factor in kidney pathophysiology | |
| Sakkas et al. | Anti-citrullinated peptides as autoantigens in rheumatoid arthritis—relevance to treatment | |
| Iwakura | Roles of IL-1 in the development of rheumatoid arthritis: consideration from mouse models | |
| ES2353273T3 (es) | Anticuerpos anti-cd28. | |
| Praveen et al. | Constitutive expression of tumor necrosis factor-alpha in cytotoxic cells of teleosts and its role in regulation of cell-mediated cytotoxicity | |
| Cortez et al. | CRTAM controls residency of gut CD4+ CD8+ T cells in the steady state and maintenance of gut CD4+ Th17 during parasitic infection | |
| WO2020082130A1 (en) | T-cell receptors and uses thereof | |
| WO2015022520A1 (en) | T cell receptors | |
| Jacques et al. | Ultra-low dose cytokines in rheumatoid arthritis, three birds with one stone as the rationale of the 2LARTH® micro-immunotherapy treatment | |
| V. Reiche et al. | Genetic polymorphisms in the chemokine and chemokine receptors: impact on clinical course and therapy of the human immunodeficiency virus type 1 infection (HIV-1) | |
| RU2018140056A (ru) | Композиции и способы с использованием т-клеток с химерным рецептором аллоантигена | |
| ES2710444T3 (es) | Un polipéptido de interleucina 34 aislado para uso en la prevención del rechazo de trasplante y el tratamiento de enfermedades autoinmunitarias | |
| JP6792559B2 (ja) | 癌治療のためのｈｌａホモ二量体の使用 | |
| US11807676B2 (en) | MHC class Ia open conformers | |
| US20210380683A1 (en) | Modulation of irf-4 and uses thereof | |
| Moritz et al. | Molecular studies reveal that A134T, G156A and G1333A SNPs in the CD177 gene are associated with atypical expression of human neutrophil antigen‐2 | |
| Ravindranath et al. | Four faces of cell-surface HLA class-I: their antigenic and immunogenic divergence generating novel targets for vaccines | |
| Ciszak et al. | Alterations in the expression of signal-transducing CD3ζ chain in T cells from patients with chronic inflammatory/autoimmune diseases | |
| CN116790737B (zh) | Pik3ip1蛋白在制备诊断或治疗自身免疫性疾病的试剂或药物中的应用 | |
| Umetsu et al. | TIM gene family and their role in atopic diseases | |
| Socié et al. | Immune biology of allogeneic hematopoietic stem cell transplantation: models in discovery and translation |